Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?

ConclusionAccording to significant improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a bronchodilator agent in group A COPD patients, especially in emphysema-dominant phenotype.

Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research